AI Article Synopsis

  • Idiopathic pulmonary fibrosis is a serious and progressive disease, and the role of matrix metalloproteinase-2 (MMP-2) in this condition is not well understood.
  • A study using transgenic mice that overexpress MMP-2 showed reduced inflammation and fibrosis compared to regular mice after lung injury caused by bleomycin.
  • The findings suggest that MMP-2 helps protect against pulmonary fibrosis by decreasing cell death (apoptosis) in the lung's epithelial cells.

Article Abstract

Idiopathic pulmonary fibrosis is a progressive and fatal disease with a poor prognosis. Matrix metalloproteinase-2 is involved in the pathogenesis of organ fibrosis. The role of matrix metalloproteinase-2 in lung fibrosis is unclear. This study evaluated whether overexpression of matrix metalloproteinase-2 affects the development of pulmonary fibrosis. Lung fibrosis was induced by bleomycin in wild-type mice and transgenic mice overexpressing human matrix metalloproteinase-2. Mice expressing human matrix metalloproteinase-2 showed significantly decreased infiltration of inflammatory cells and inflammatory and fibrotic cytokines in the lungs compared to wild-type mice after induction of lung injury and fibrosis with bleomycin. The computed tomography score, Ashcroft score of fibrosis, and lung collagen deposition were significantly reduced in human matrix metalloproteinase transgenic mice compared to wild-type mice. The expression of anti-apoptotic genes was significantly increased, while caspase-3 activity was significantly reduced in the lungs of matrix metalloproteinase-2 transgenic mice compared to wild-type mice. Active matrix metalloproteinase-2 significantly decreased bleomycin-induced apoptosis in alveolar epithelial cells. Matrix metalloproteinase-2 appears to protect against pulmonary fibrosis by inhibiting apoptosis of lung epithelial cells.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095307PMC
http://dx.doi.org/10.3390/ijms24076695DOI Listing

Publication Analysis

Top Keywords

matrix metalloproteinase-2
36
pulmonary fibrosis
16
wild-type mice
16
transgenic mice
12
human matrix
12
compared wild-type
12
matrix
10
fibrosis
9
metalloproteinase-2
9
lung fibrosis
8

Similar Publications

Cysteinyl leukotrienes (LTs) and their receptors are involved in the pathogenesis of abdominal aortic aneurysms (AAAs). However, whether CysLT1 receptor antagonists such as montelukast can influence experimental nondissecting AAA remains unclear. Nondissecting AAAs were induced in C57BL/6J mice by transient aortic luminal infusion of porcine pancreatic elastase (PPE).

View Article and Find Full Text PDF

Thymidine phosphorylase (TYMP) promotes platelet activation and thrombosis while suppressing vascular smooth muscle cell (VSMC) proliferation. Both processes are central to the development and progression of abdominal aortic aneurysms (AAAs). We hypothesize that TYMP plays a role in AAA development.

View Article and Find Full Text PDF

Background/aim: Organometallic complexes can decrease adhesion, migration, invasion of cancer cells, mainly through regulation of the extracellular matrix and therefore act against metastases. The aim was to investigate the anti-invasive properties of a rhenium-based metal compound, rhenium(I)-diselenoether (Re-diSe) and its effects on matrix metalloproteinase MMP-2, a key player in metastatic processes, in cultured MDA-MB231 triple-negative breast cancer cells.

Materials And Methods: Matrigel was utilized to assess cancer cell adhesion to the extracellular matrix.

View Article and Find Full Text PDF

Cystitis glandularis (CG), known as a pre-gradual lesion in the bladder, is the pathological changes in the vesical mucosa characterized by inflammatory invasion and chronic obstruction. Clinically, effective treatment against CG is prescribed only when using drug therapy. Fucoidan, the naturally extractive polysaccharide, is well-reported bioactive compound with anti-inflammatory and immunoregulatory properties.

View Article and Find Full Text PDF

Development of a Peptide-Based Tumor-Activated Checkpoint Inhibitor for Cancer Immunotherapy.

Acta Biomater

December 2024

Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO 64108, USA. Electronic address:

Antibody-based checkpoint inhibitors have achieved great success in cancer immunotherapy, but their uncontrollable immune-related adverse events remain a major challenge. In this study, we developed a tumor-activated nanoparticle that is specifically active in tumors but not in normal tissues. We discovered a short anti-PD-L1 peptide that blocks the PD-1/PD-L1 interaction.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!